ANNEX I

SUMMARY OF PRODUCT CHARACTERISTICS
1. NAME OF THE MEDICINAL PRODUCT

Glidipion 15 mg tablets
Glidipion 30 mg tablets
Glidipion 45 mg tablets

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Glidipion 15 mg tablets
Each tablet contains 15 mg of pioglitazone (as hydrochloride).

Excipients with known effect:
Each tablet contains 37.77 mg of lactose monohydrate (see section 4.4).

Glidipion 30 mg tablets
Each tablet contains 30 mg of pioglitazone (as hydrochloride).

Excipients with known effect:
Each tablet contains 75.54 mg of lactose monohydrate (see section 4.4).

Glidipion 45 mg tablets
Each tablet contains 45 mg of pioglitazone (as hydrochloride).

Excipients with known effect:
Each tablet contains 113.31 mg of lactose monohydrate (see section 4.4).

For the full list of excipients, see section 6.1.

3. PHARMACEUTICAL FORM

Tablet.

Glidipion 15 mg tablets
The tablets are white, round, flat, bevelled, 5.5 mm in diameter and engraved with ‘TZ15’ on one side.

Glidipion 30 mg tablets
The tablets are white, round, flat, bevelled, 7 mm in diameter and engraved with ‘TZ30’ on one side.

Glidipion 45 mg tablets
The tablets are white, round, flat, bevelled, 8 mm in diameter and engraved with ‘TZ45’ on one side.

4. CLINICAL PARTICULARS

4.1 Therapeutic indications

Pioglitazone is indicated as second or third line treatment of type 2 diabetes mellitus as described below:

as monotherapy
- in adult patients (particularly overweight patients) inadequately controlled by diet and exercise for whom metformin is inappropriate because of contraindications or intolerance.
as dual oral therapy in combination with
- metformin, in adult patients (particularly overweight patients) with insufficient glycaemic control despite maximal tolerated dose of monotherapy with metformin.
- a sulphonylurea, only in adult patients who show intolerance to metformin or for whom metformin is contraindicated, with insufficient glycaemic control despite maximal tolerated dose of monotherapy with a sulphonylurea.

as triple oral therapy in combination with
- metformin and a sulphonylurea, in adult patients (particularly overweight patients) with insufficient glycaemic control despite dual oral therapy.
- Pioglitazone is also indicated for combination with insulin in type 2 diabetes mellitus adult patients with insufficient glycaemic control on insulin for whom metformin is inappropriate because of contraindications or intolerance (see section 4.4).

After initiation of therapy with pioglitazone, patients should be reviewed after 3 to 6 months to assess adequacy of response to treatment (e.g. reduction in HbA1c). In patients who fail to show an adequate response, pioglitazone should be discontinued. In light of potential risks with prolonged therapy, prescribers should confirm at subsequent routine reviews that the benefit of pioglitazone is maintained (see section 4.4).

4.2 Posology and method of administration

Posology
Pioglitazone treatment may be initiated at 15 mg or 30 mg once daily. The dose may be increased in increments up to 45 mg once daily.

In combination with insulin, the current insulin dose can be continued upon initiation of pioglitazone therapy. If patients report hypoglycaemia, the dose of insulin should be decreased.

Special population

Elderly
No dose adjustment is necessary for elderly patients (see section 5.2). Physicians should start treatment with the lowest available dose and increase the dose gradually, particularly when pioglitazone is used in combination with insulin (see section 4.4 Fluid retention and cardiac failure).

Renal impairment
No dose adjustment is necessary in patients with impaired renal function (creatinine clearance <4 ml/min) (see section 5.2). No information is available from dialysed patients, therefore pioglitazone should not be used in such patients.

Hepatic impairment
Pioglitazone should not be used in patients with hepatic impairment (see section 4.3 and 4.4).

Paediatric population
The safety and efficacy of pioglitazone in children and adolescents under 18 years of age have not been established. No data are available.
Method of administration

Pioglitazone tablets are taken orally once daily with or without food. Tablets should be swallowed with a glass of water.

4.3 Contraindications

Pioglitazone is contraindicated in patients with:

- hypersensitivity to the active substance or to any of the excipients
- cardiac failure or history of cardiac failure (NYHA stages I to IV)
- hepatic impairment
- diabetic ketoacidosis
- current bladder cancer or a history of bladder cancer
- uninvestigated macroscopic haematuria.

4.4 Special warnings and precautions for use

Fluid retention and cardiac failure

Pioglitazone can cause fluid retention, which may exacerbate or precipitate heart failure. When treating patients who have at least one risk factor for development of congestive heart failure (e.g., prior myocardial infarction or symptomatic coronary artery disease, or the elderly), physicians should start with the lowest available dose and increase the dose gradually. Patients should be observed for signs and symptoms of heart failure, weight gain, or oedema; particularly those with reduced cardiac reserve. There have been post-marketing cases of cardiac failure reported when pioglitazone was used in combination with insulin or in patients with a history of cardiac failure. Patients should be observed for signs and symptoms of heart failure, weight gain, and oedema when pioglitazone is used in combination with insulin. Since insulin and pioglitazone are both associated with fluid retention, concomitant administration may increase the risk of oedema. Post-marketing cases of peripheral oedema and cardiac failure have also been reported in patients with concomitant use of pioglitazone and nonsteroidal anti-inflammatory drugs, including selective COX-2 inhibitors. Pioglitazone should be discontinued if any deterioration in cardiac status occurs.

A cardiovascular outcome study of pioglitazone has been performed in patients under 75 years with type 2 diabetes mellitus and pre-existing major macrovascular disease. Pioglitazone or placebo was added to existing antidiabetic and cardiovascular therapy for up to 3.5 years. This study showed an increase in reports of heart failure, however this did not lead to an increase in mortality in this study.

Elderly

Combination use with insulin should be considered with caution in the elderly because of increased risk of serious heart failure.

In light of age-related risks (especially bladder cancer, fractures, and heart failure), the balance of benefits and risks should be considered carefully both before and during treatment in the elderly.

Bladder cancer

Cases of bladder cancer were reported more frequently in a meta-analysis of controlled clinical trials with pioglitazone (19 cases from 12506 patients, 0.15%) than in control groups (7 cases from 10212 patients, 0.07%) HR=2.64 (95% CI 1.11-6.31, P=0.029). After excluding patients in whom exposure to study drug was less than one year at the time of diagnosis of bladder cancer, there were 7 cases (0.06%) on pioglitazone and 2 cases (0.02%) in control groups. Epidemiological studies have also suggested a small increased risk of bladder cancer in diabetic patients treated with pioglitazone, although not all studies identified a statistically significant increased risk.
Risk factors for bladder cancer should be assessed before initiating pioglitazone treatment (risks include age, smoking history, exposure to some occupational or chemotherapy agents e.g. cyclophosphamide or prior radiation treatment in the pelvic region). Any macroscopic haematuria should be investigated before starting pioglitazone therapy.

Patients should be advised to promptly seek the attention of their physician if macroscopic haematuria or other symptoms such as dysuria or urinary urgency develop during treatment.

**Monitoring of liver function**

There have been rare reports of hepatocellular dysfunction during post-marketing experience (see section 4.8). It is recommended, therefore, that patients treated with pioglitazone undergo periodic monitoring of liver enzymes. Liver enzymes should be checked prior to the initiation of therapy with pioglitazone in all patients. Therapy with pioglitazone should not be initiated in patients with increased baseline liver enzyme levels (ALT > 2.5 X upper limit of normal) or with any other evidence of liver disease.

Following initiation of therapy with pioglitazone, it is recommended that liver enzymes be monitored periodically based on clinical judgement. If ALT levels are increased to 3 X upper limit of normal during pioglitazone therapy, liver enzyme levels should be reassessed as soon as possible. If ALT levels remain > 3 X the upper limit of normal, therapy should be discontinued. If any patient develops symptoms suggesting hepatic dysfunction, which may include unexplained nausea, vomiting, abdominal pain, fatigue, anorexia and/or dark urine, liver enzymes should be checked. The decision whether to continue the patient on therapy with pioglitazone should be guided by clinical judgement pending laboratory evaluations. If jaundice is observed, the medicinal product should be discontinued.

**Weight gain**

In clinical trials with pioglitazone there was evidence of dose related weight gain, which may be due to fat accumulation and in some cases associated with fluid retention. In some cases weight increase may be a symptom of cardiac failure, therefore weight should be closely monitored. Part of the treatment of diabetes is dietary control. Patients should be advised to adhere strictly to a calorie-controlled diet.

**Haematology**

There was a small reduction in mean haemoglobin (4% relative reduction) and haematocrit (4.1% relative reduction) during therapy with pioglitazone, consistent with haemodilution. Similar changes were seen in metformin (haemoglobin 3–4% and haematocrit 3.6–4.1% relative reductions) and to a lesser extent sulphonylurea and insulin (haemoglobin 1–2% and haematocrit 1–3.2% relative reductions) treated patients in comparative controlled trials with pioglitazone.

**Hypoglycaemia**

As a consequence of increased insulin sensitivity, patients receiving pioglitazone in dual or triple oral therapy with a sulphonylurea or in dual therapy with insulin may be at risk for dose-related hypoglycaemia, and a reduction in the dose of the sulphonylurea or insulin may be necessary.

**Eye disorders**

Post-marketing reports of new-onset or worsening diabetic macular oedema with decreased visual acuity have been reported with thiazolidinediones, including pioglitazone. Many of these patients reported concurrent peripheral oedema. It is unclear whether or not there is a direct association between pioglitazone and macular oedema but prescribers should be alert to the possibility of macular oedema if patients report disturbances in visual acuity; an appropriate ophthalmological referral should be considered.
An increased incidence in bone fractures in women was seen in a pooled analysis of adverse reactions of bone fracture from randomised, controlled, double blind clinical trials in over 8100 pioglitazone and 7400 comparator treated patients, on treatment for up to 3.5 years.

Fractures were observed in 2.6% of women taking pioglitazone compared to 1.7% of women treated with a comparator. No increase in fracture rates was observed in men treated with pioglitazone (1.3%) versus comparator (1.5%).

The fracture incidence calculated was 1.9 fractures per 100 patient years in women treated with pioglitazone and 1.1 fractures per 100 patient years in women treated with a comparator. The observed excess risk of fractures for women in this dataset on pioglitazone is therefore 0.8 fractures per 100 patient years of use.

In the 3.5 year cardiovascular risk PROactive study, 44/870 (5.1%; 1.0 fractures per 100 patient years) of pioglitazone-treated female patients experienced fractures compared to 23/905 (2.5%; 0.5 fractures per 100 patient years) of female patients treated with comparator. No increase in fracture rates was observed in men treated with pioglitazone (1.7%) versus comparator (2.1%).

Some epidemiological studies have suggested a similarly increased risk of fracture in both men and women.

The risk of fractures should be considered in the long term care of patients treated with pioglitazone (see section 4.8).

As a consequence of enhancing insulin action, pioglitazone treatment in patients with polycystic ovarian syndrome may result in resumption of ovulation. These patients may be at risk of pregnancy. Patients should be aware of the risk of pregnancy and if a patient wishes to become pregnant or if pregnancy occurs, the treatment should be discontinued (see section 4.6).

Pioglitazone should be used with caution during concomitant administration of cytochrome P450 2C8 inhibitors (e.g. gemfibrozil) or inducers (e.g. rifampicin). Glycaemic control should be monitored closely. Pioglitazone dose adjustment within the recommended posology or changes in diabetic treatment should be considered (see section 4.5).

Glidipion tablets contain lactose monohydrate and therefore should not be administered to patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption.

4.5 Interaction with other medicinal products and other forms of interaction

Interaction studies have shown that pioglitazone has no relevant effect on either the pharmacokinetics or pharmacodynamics of digoxin, warfarin, phenprocoumon and metformin. Co-administration of pioglitazone with sulphonylureas does not appear to affect the pharmacokinetics of the sulphonylurea. Studies in man suggest no induction of the main inducible cytochrome P450, 1A, 2C8/9 and 3A4. In vitro studies have shown no inhibition of any subtype of cytochrome P450. Interactions with substances metabolised by these enzymes, e.g. oral contraceptives, cyclosporin, calcium channel blockers, and HMGCoA reductase inhibitors are not to be expected.

Co-administration of pioglitazone with gemfibrozil (an inhibitor of cytochrome P450 2C8) is reported to result in a 3-fold increase in AUC of pioglitazone. Since there is a potential for an increase in dose-related adverse events, a decrease in the dose of pioglitazone may be needed when gemfibrozil is concomitantly administered. Close monitoring of glycaemic control should be considered (see section 4.4). Co-administration of pioglitazone with rifampicin (an inducer of cytochrome P450 2C8) is reported to result in a 54% decrease in AUC of pioglitazone. The pioglitazone dose may need to be
increased when rifampicin is concomitantly administered. Close monitoring of glycaemic control should be considered (see section 4.4).

4.6 Fertility, pregnancy and lactation

Pregnancy

There are no adequate human data to determine the safety of pioglitazone during pregnancy. Foetal growth restriction was apparent in animal studies with pioglitazone. This was attributable to the action of pioglitazone in diminishing the maternal hyperinsulinaemia and increased insulin resistance that occurs during pregnancy, thereby reducing the availability of metabolic substrates for foetal growth. The relevance of such a mechanism in humans is unclear and pioglitazone should not be used in pregnancy.

Breastfeeding

Pioglitazone has been shown to be present in the milk of lactating rats. It is not known whether pioglitazone is secreted in human milk. Therefore, pioglitazone should not be administered to breast-feeding women.

Fertility

In animal fertility studies there was no effect on copulation, impregnation or fertility index.

4.7 Effects on ability to drive and use machines

Glidipion has no or negligible effect on the ability to drive and use machines. However patients who experience visual disturbance should be cautious when driving or using machines.

4.8 Undesirable effects

Adverse reactions reported in excess (>0.5%) of placebo and as more than an isolated case in patients receiving pioglitazone in double-blind studies are listed below as MedDRA preferred term by system organ class and absolute frequency. Frequencies are defined as: very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1,000 to <1/100); rare (≥1/10,000 to <1/1,000); very rare (<1/10,000); not known (cannot be estimated from the available data). Within each frequency grouping, adverse reactions are presented in order of decreasing incidence and seriousness.

<table>
<thead>
<tr>
<th>Adverse reaction</th>
<th>Frequency of adverse reactions of pioglitazone by treatment regimen</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Frequency of adverse reactions of pioglitazone by treatment regimen</td>
</tr>
<tr>
<td></td>
<td>Combination</td>
</tr>
<tr>
<td></td>
<td>Mono-therapy</td>
</tr>
<tr>
<td>Infections and infestations</td>
<td></td>
</tr>
<tr>
<td>upper respiratory tract infection</td>
<td>common</td>
</tr>
<tr>
<td>bronchitis</td>
<td></td>
</tr>
<tr>
<td>sinusitis</td>
<td>uncommon</td>
</tr>
<tr>
<td>Blood and lymphatic system disorders</td>
<td></td>
</tr>
<tr>
<td>anaemia</td>
<td></td>
</tr>
<tr>
<td>Immune System</td>
<td></td>
</tr>
<tr>
<td>Adverse reaction</td>
<td>Frequency of adverse reactions of pioglitazone by treatment regimen</td>
</tr>
<tr>
<td>------------------</td>
<td>---------------------------------------------------------------</td>
</tr>
<tr>
<td></td>
<td>Monotherapy</td>
</tr>
<tr>
<td>Disorders</td>
<td></td>
</tr>
<tr>
<td>Hypersensitivity and allergic reactions</td>
<td>not known</td>
</tr>
<tr>
<td>Metabolism and nutrition disorders</td>
<td></td>
</tr>
<tr>
<td>hypo-glycaemia</td>
<td></td>
</tr>
<tr>
<td>appetite increased</td>
<td></td>
</tr>
<tr>
<td>Nervous system disorders</td>
<td></td>
</tr>
<tr>
<td>hypo-aesthesia</td>
<td>common</td>
</tr>
<tr>
<td>headache</td>
<td>common</td>
</tr>
<tr>
<td>dizziness</td>
<td></td>
</tr>
<tr>
<td>insomnia</td>
<td>uncommon</td>
</tr>
<tr>
<td>Eye disorders</td>
<td></td>
</tr>
<tr>
<td>visual disturbance</td>
<td></td>
</tr>
<tr>
<td>macular oedema</td>
<td>not known</td>
</tr>
<tr>
<td>Ear and labyrinth disorders</td>
<td></td>
</tr>
<tr>
<td>vertigo</td>
<td></td>
</tr>
<tr>
<td>Cardiac disorders</td>
<td></td>
</tr>
<tr>
<td>heart failure</td>
<td></td>
</tr>
<tr>
<td>Neoplasms benign, malignant and unspecified (including cysts and polyps)</td>
<td></td>
</tr>
<tr>
<td>bladder cancer</td>
<td>uncommon</td>
</tr>
<tr>
<td>Respiratory, thoracic and mediastinal disorders</td>
<td></td>
</tr>
<tr>
<td>dyspnoea</td>
<td></td>
</tr>
<tr>
<td>Gastrointestinal disorders</td>
<td></td>
</tr>
<tr>
<td>flatulence</td>
<td></td>
</tr>
<tr>
<td>Skin and subcutaneous tissue disorders</td>
<td></td>
</tr>
<tr>
<td>sweating</td>
<td></td>
</tr>
</tbody>
</table>
**Adverse reaction** | Frequency of adverse reactions of pioglitazone by treatment regimen |
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Mono-therapy</td>
</tr>
<tr>
<td><strong>Musculoskeletal and connective tissue disorders</strong></td>
<td></td>
</tr>
<tr>
<td>fracture bone</td>
<td>common</td>
</tr>
<tr>
<td>arthralgia</td>
<td>common</td>
</tr>
<tr>
<td>back pain</td>
<td></td>
</tr>
<tr>
<td><strong>Renal and urinary disorders</strong></td>
<td></td>
</tr>
<tr>
<td>haematuria</td>
<td></td>
</tr>
<tr>
<td>glycosuria</td>
<td></td>
</tr>
<tr>
<td>proteinuria</td>
<td></td>
</tr>
<tr>
<td><strong>Reproductive system and breast disorders</strong></td>
<td></td>
</tr>
<tr>
<td>erectile dysfunction</td>
<td></td>
</tr>
<tr>
<td><strong>General disorders and administration site conditions</strong></td>
<td></td>
</tr>
<tr>
<td>oedema</td>
<td></td>
</tr>
<tr>
<td>fatigue</td>
<td></td>
</tr>
<tr>
<td><strong>Investigations</strong></td>
<td></td>
</tr>
<tr>
<td>weight increased</td>
<td>common</td>
</tr>
<tr>
<td>blood creatine phospho-kinase increased</td>
<td></td>
</tr>
<tr>
<td>increased lactic dehydrogenase</td>
<td></td>
</tr>
<tr>
<td>Alanine aminotransferase increased</td>
<td>not known</td>
</tr>
</tbody>
</table>

Description of selected adverse reactions

1. Postmarketing reports of hypersensitivity reactions in patients treated with pioglitazone have been reported. These reactions include anaphylaxis, angioedema, and urticaria.

2. Visual disturbance has been reported mainly early in treatment and is related to changes in blood glucose due to temporary alteration in the turgidity and refractive index of the lens as seen with other hypoglycaemic treatments.

3. In controlled clinical trials the incidence of reports of heart failure with pioglitazone treatment was the same as in placebo, metformin and sulphonylurea treatment groups, but was increased when used in combination therapy with insulin. In an outcome study of patients with pre-existing major...
macrovascular disease, the incidence of serious heart failure was 1.6% higher with pioglitazone than with placebo, when added to therapy that included insulin. However, this did not lead to an increase in mortality in this study. In this study in patients receiving pioglitazone and insulin, a higher percentage of patients with heart failure was observed in patients aged ≥65 years compared with those less than 65 years (9.7% compared to 4.0%). In patients on insulin with no pioglitazone the incidence of heart failure was 8.2% in those ≥65 years compared to 4.0% in patients less than 65 years. Heart failure has been reported with marketing use of pioglitazone, and more frequently when pioglitazone was used in combination with insulin or in patients with a history of cardiac failure.

4 A pooled analysis was conducted of adverse reactions of bone fractures from randomised, comparator controlled, double blind clinical trials in over 8100 patients in the pioglitazone-treated groups and 7400 in the comparator-treated groups of up to 3.5 years duration. A higher rate of fractures was observed in women taking pioglitazone (2.6%) versus comparator (1.7%). No increase in fracture rates was observed in men treated with pioglitazone (1.3%) versus comparator (1.5%). In the 3.5 year PROactive study, 44/870 (5.1%) of pioglitazone-treated female patients experienced fractures compared to 23/905 (2.5%) of female patients treated with comparator. No increase in fracture rates was observed in men treated with pioglitazone (1.7%) versus comparator (2.1%). Post-marketing, bone fractures have been reported in both male and female patients (see section 4.4).

5 Oedema was reported in 6–9% of patients treated with pioglitazone over one year in controlled clinical trials. The oedema rates for comparator groups (sulphonylurea, metformin) were 2–5%. The reports of oedema were generally mild to moderate and usually did not require discontinuation of treatment.

6 In active comparator controlled trials mean weight increase with pioglitazone given as monotherapy was 2–3 kg over one year. This is similar to that seen in a sulphonylurea active comparator group. In combination trials pioglitazone added to metformin resulted in mean weight increase over one year of 1.5 kg and added to a sulphonylurea of 2.8 kg. In comparator groups, addition of sulphonylurea to metformin resulted in a mean weight gain of 1.3 kg and addition of metformin to a sulphonylurea a mean weight loss of 1.0 kg.

7 In clinical trials with pioglitazone the incidence of elevations of ALT greater than three times the upper limit of normal was equal to placebo but less than that seen in metformin or sulphonylurea comparator groups. Mean levels of liver enzymes decreased with treatment with pioglitazone. Rare cases of elevated liver enzymes and hepatocellular dysfunction have occurred in post-marketing experience. Although in very rare cases fatal outcome has been reported, causal relationship has not been established.

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system listed in Appendix V.

4.9 Overdose

In clinical studies, patients have taken pioglitazone at higher than the recommended highest dose of 45 mg daily. The maximum reported dose of 120 mg/day for four days, then 180 mg/day for seven days was not associated with any symptoms.

Hypoglycaemia may occur in combination with sulphonylureas or insulin. Symptomatic and general supportive measures should be taken in case of overdose.
5. PHARMACOLOGICAL PROPERTIES

5.1 Pharmacodynamic properties

Pharmacotherapeutic group: Drugs used in diabetes, blood glucose lowering drugs, excl. insulins; ATC code: A10BG03.

Pioglitazone effects may be mediated by a reduction of insulin resistance. Pioglitazone appears to act via activation of specific nuclear receptors (peroxisome proliferator activated receptor gamma) leading to increased insulin sensitivity of liver, fat and skeletal muscle cells in animals. Treatment with pioglitazone has been shown to reduce hepatic glucose output and to increase peripheral glucose disposal in the case of insulin resistance.

Fasting and postprandial glycaemic control is improved in patients with type 2 diabetes mellitus. The improved glycaemic control is associated with a reduction in both fasting and postprandial plasma insulin concentrations. A clinical trial of pioglitazone vs. gliclazide as monotherapy was extended to two years in order to assess time to treatment failure (defined as appearance of HbA1c ≥ 8.0% after the first six months of therapy). Kaplan-Meier analysis showed shorter time to treatment failure in patients treated with gliclazide, compared with pioglitazone. At two years, glycaemic control (defined as HbA1c < 8.0%) was sustained in 69% of patients treated with pioglitazone, compared with 50% of patients on gliclazide. In a two-year study of combination therapy comparing pioglitazone with gliclazide when added to metformin, glycaemic control measured as mean change from baseline in HbA1c was similar between treatment groups after one year. The rate of deterioration of HbA1c during the second year was less with pioglitazone than with gliclazide.

In a placebo controlled trial, patients with inadequate glycaemic control despite a three month insulin optimisation period were randomised to pioglitazone or placebo for 12 months. Patients receiving pioglitazone had a mean reduction in HbA1c of 0.45% compared with those continuing on insulin alone, and a reduction of insulin dose in the pioglitazone treated group.

HOMA analysis shows that pioglitazone improves beta cell function as well as increasing insulin sensitivity. Two-year clinical studies have shown maintenance of this effect.

In one year clinical trials, pioglitazone consistently gave a statistically significant reduction in the albumin/creatinine ratio compared to baseline.

The effect of pioglitazone (45 mg monotherapy vs. placebo) was studied in a small 18-week trial in type 2 diabetes. Pioglitazone was associated with significant weight gain. Visceral fat was significantly decreased, while there was an increase in extra-abdominal fat mass. Similar changes in body fat distribution on pioglitazone have been accompanied by an improvement in insulin sensitivity. In most clinical trials, reduced total plasma triglycerides and free fatty acids, and increased HDL-cholesterol levels were observed as compared to placebo, with small, but not clinically significant increases in LDL-cholesterol levels.

In clinical trials of up to two years duration, pioglitazone reduced total plasma triglycerides and free fatty acids, and increased HDL-cholesterol levels, compared with placebo, metformin or gliclazide. Pioglitazone did not cause statistically significant increases in LDL-cholesterol levels compared with placebo, whilst reductions were observed with metformin and gliclazide. In a 20-week study, as well as reducing fasting triglycerides, pioglitazone reduced post prandial hypertriglyceridaemia through an effect on both absorbed and hepatically synthesised triglycerides. These effects were independent of pioglitazone’s effects on glycaemia and were statistically significant different to glibenclamide.

In PROactive, a cardiovascular outcome study, 5238 patients with type 2 diabetes mellitus and pre-existing major macrovascular disease were randomised to pioglitazone or placebo in addition to existing antidiabetic and cardiovascular therapy, for up to 3.5 years. The study population had an average age of 62 years; the average duration of diabetes was 9.5 years. Approximately one third of patients were receiving insulin in combination with metformin and/or a sulphonylurea. To be eligible
patients had to have had one or more of the following: myocardial infarction, stroke, percutaneous cardiac intervention or coronary artery bypass graft, acute coronary syndrome, coronary artery disease, or peripheral arterial obstructive disease. Almost half of the patients had a previous myocardial infarction and approximately 20% had had a stroke. Approximately half of the study population had at least two of the cardiovascular history entry criteria. Almost all subjects (95%) were receiving cardiovascular medicinal products (beta blockers, ACE inhibitors, angiotensin II antagonists, calcium channel blockers, nitrates, diuretics, aspirin, statins, fibrates).

Although the study failed regarding its primary endpoint, which was a composite of all-cause mortality, non-fatal myocardial infarction, stroke, acute coronary syndrome, major leg amputation, coronary revascularisation and leg revascularisation, the results suggest that there are no long-term cardiovascular concerns regarding use of pioglitazone. However, the incidences of oedema, weight gain and heart failure were increased. No increase in mortality from heart failure was observed.

**Paediatric population**

The European Medicines Agency has waived the obligation to submit the results of studies with pioglitazone in all subsets of the paediatric population in Type 2 Diabetes Mellitus. See section 4.2 for information on paediatric use.

**5.2 Pharmacokinetic properties**

**Absorption**

Following oral administration, pioglitazone is rapidly absorbed, and peak plasma concentrations of unchanged pioglitazone are usually achieved 2 hours after administration. Proportional increases of the plasma concentration were observed for doses from 2-60 mg. Steady state is achieved after 4-7 days of dosing. Repeated dosing does not result in accumulation of the compound or metabolites. Absorption is not influenced by food intake. Absolute bioavailability is greater than 80%.

**Distribution**

The estimated volume of distribution in humans is 0.25 l/kg.

Pioglitazone and all active metabolites are extensively bound to plasma protein (> 99%).

**Biotransformation**

Pioglitazone undergoes extensive hepatic metabolism by hydroxylation of aliphatic methylene groups. This is predominantly via cytochrome P450 2C8 although other isoforms may be involved to a lesser degree. Three of the six identified metabolites are active (M-II, M-III, and M-IV). When activity, concentrations and protein binding are taken into account, pioglitazone and metabolite M-III contribute equally to efficacy. On this basis M-IV contribution to efficacy is approximately three-fold that of pioglitazone, whilst the relative efficacy of M-II is minimal.

*In vitro* studies have shown no evidence that pioglitazone inhibits any subtype of cytochrome P450. There is no induction of the main inducible P450 isoenzymes 1A, 2C8/9, and 3A4 in man.

Interaction studies have shown that pioglitazone has no relevant effect on either the pharmacokinetics or pharmacodynamics of digoxin, warfarin, phenprocoumon and metformin. Concomitant administration of pioglitazone with gemfibrozil (an inhibitor of cytochrome P450 2C8) or with rifampicin (an inducer of cytochrome P450 2C8) is reported to increase or decrease, respectively, the plasma concentration of pioglitazone (see section 4.5).
Elimination

Following oral administration of radiolabelled pioglitazone to man, recovered label was mainly in faeces (55%) and a lesser amount in urine (45%). In animals, only a small amount of unchanged pioglitazone can be detected in either urine or faeces. The mean plasma elimination half-life of unchanged pioglitazone in man is 5 to 6 hours and for its total active metabolites 16 to 23 hours.

Elderly

Steady state pharmacokinetics are similar in patients age 65 and over and young subjects.

Patients with renal impairment

In patients with renal impairment, plasma concentrations of pioglitazone and its metabolites are lower than those seen in subjects with normal renal function, but oral clearance of parent substance is similar. Thus free (unbound) pioglitazone concentration is unchanged.

Patients with hepatic impairment

Total plasma concentration of pioglitazone is unchanged, but with an increased volume of distribution. Intrinsic clearance is therefore reduced, coupled with a higher unbound fraction of pioglitazone.

5.3 Preclinical safety data

In toxicology studies, plasma volume expansion with haemodilution, anaemia, and reversible eccentric cardiac hypertrophy was consistently apparent after repeated dosing of mice, rats, dogs, and monkeys. In addition, increased fatty deposition and infiltration were observed. These findings were observed across species at plasma concentrations ≤ 4 times the clinical exposure. Foetal growth restriction was apparent in animal studies with pioglitazone. This was attributable to the action of pioglitazone in diminishing the maternal hyperinsulinaemia and increased insulin resistance that occurs during pregnancy thereby reducing the availability of metabolic substrates for foetal growth.

Pioglitazone was devoid of genotoxic potential in a comprehensive battery of in vivo and in vitro genotoxicity assays. An increased incidence of hyperplasia (males and females) and tumours (males) of the urinary bladder epithelium was apparent in rats treated with pioglitazone for up to 2 years.

The formation and presence of urinary calculi with subsequent irritation and hyperplasia was postulated as the mechanistic basis for the observed tumourigenic response in the male rat. A 24-month mechanistic study in male rats demonstrated that administration of pioglitazone resulted in an increased incidence of hyperplastic changes in the bladder. Dietary acidification significantly decreased but did not abolish the incidence of tumours. The presence of microcrystals exacerbated the hyperplastic response but was not considered to be the primary cause of hyperplastic changes. The relevance to humans of the tumourigenic findings in the male rat cannot be excluded.

There was no tumorigenic response in mice of either sex. Hyperplasia of the urinary bladder was not seen in dogs or monkeys treated with pioglitazone for up to 12 months.

In an animal model of familial adenomatous polyposis (FAP), treatment with two other thiazolidinediones increased tumour multiplicity in the colon. The relevance of this finding is unknown.

Environmental Risk Assessment: no environmental impact is anticipated from the clinical use of pioglitazone.
6. PHARMACEUTICAL PARTICULARS

6.1 List of excipients

Carmellose calcium
Hydroxypropylcellulose
Lactose monohydrate
Magnesium stearate

6.2 Incompatibilities

Not applicable.

6.3 Shelf life

3 years.

6.4 Special precautions for storage

This medicinal product does not require any special storage conditions.

6.5 Nature and contents of container

Aluminium/aluminium blisters, packs of 14, 28, 30, 50, 56, 84, 98 and 100 tablets.

The packs with 14, 28, 56, 84 and 98 tablets contain blisters with abbreviations for days of the week printed on the blister (Mon., Tue., Wed., Thu., Fri., Sat., Sun.).

Not all pack sizes may be marketed.

6.6 Special precautions for disposal

No special requirements.

7. MARKETING AUTHORISATION HOLDER

Actavis Group PTC ehf
Reykjavíkurvegi 76-78
220 Hafnarfjörður
Iceland

8. MARKETING AUTHORISATION NUMBER(S)

EU/1/12/756/001
EU/1/12/756/002
EU/1/12/756/003
EU/1/12/756/004
EU/1/12/756/005
EU/1/12/756/006
EU/1/12/756/007
EU/1/12/756/008
EU/1/12/756/009
EU/1/12/756/010
EU/1/12/756/011
EU/1/12/756/012
9.  DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

Date of first authorisation: 15 March 2012
Date of latest renewal: 11 November 2016

10.  DATE OF REVISION OF THE TEXT

Detailed information on this medicinal product is available on the website of the European Medicines Agency http://www.ema.europa.eu/.
ANNEX II

A. MANUFACTURER RESPONSIBLE FOR BATCH RELEASE

B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE

C. OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION

D. CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT
A. MANUFACTURER RESPONSIBLE FOR BATCH RELEASE

Name and address of the manufacturer responsible for batch release

Actavis Ltd.
BLB016 Bulebel Industrial Estate
Zejtun ZTN 3000
Malta

B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE

Medicinal product subject to medical prescription.

C. OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION

- Periodic safety update reports (PSURs)

The requirements for submission of PSURs for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal.

D. CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT

- Risk management plan (RMP)

The marketing authorisation holder (MAH) shall perform the required pharmacovigilance activities and interventions detailed in the agreed RMP presented in Module 1.8.2 of the marketing authorisation and any agreed subsequent updates of the RMP.

An updated RMP should be submitted:
- At the request of the European Medicines Agency;
- Whenever the risk management system is modified, especially as the result of new information being received that may lead to a significant change to the benefit/risk profile or as the result of an important (pharmacovigilance or risk minimisation) milestone being reached.
ANNEX III

LABELLING AND PACKAGE LEAFLET

Medicinal Product no longer authorised
A. LABELLING

Medicinal Product no longer authorised
### PARTICULARS TO APPEAR ON THE OUTER PACKAGING CARTON

#### 1. NAME OF THE MEDICINAL PRODUCT

Glidipion 15 mg tablets

pioglitazone

#### 2. STATEMENT OF ACTIVE SUBSTANCE(S)

Each tablet contains 15 mg pioglitazone (as hydrochloride).

#### 3. LIST OF EXCIPIENTS

Contains lactose monohydrate. See leaflet for further information.

#### 4. PHARMACEUTICAL FORM AND CONTENTS

<table>
<thead>
<tr>
<th>Quantity</th>
</tr>
</thead>
<tbody>
<tr>
<td>14 tablets</td>
</tr>
<tr>
<td>28 tablets</td>
</tr>
<tr>
<td>30 tablets</td>
</tr>
<tr>
<td>50 tablets</td>
</tr>
<tr>
<td>56 tablets</td>
</tr>
<tr>
<td>84 tablets</td>
</tr>
<tr>
<td>90 tablets</td>
</tr>
<tr>
<td>98 tablets</td>
</tr>
<tr>
<td>100 tablets</td>
</tr>
</tbody>
</table>

#### 5. METHOD AND ROUTE(S) OF ADMINISTRATION

Read the package leaflet before use.

Oral use.

#### 6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN

Keep out of the sight and reach of children.

#### 7. OTHER SPECIAL WARNING(S), IF NECESSARY

#### 8. EXPIRY DATE

EXP

#### 9. SPECIAL STORAGE CONDITIONS

Medicinal Product no longer authorised.
10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE

11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER

Actavis Group PTC ehf.
220 Hafnarfjörður
Iceland

12. MARKETING AUTHORISATION NUMBER(S)

<table>
<thead>
<tr>
<th>Number</th>
<th>Tablets</th>
</tr>
</thead>
<tbody>
<tr>
<td>EU/1/12/756/001</td>
<td>14</td>
</tr>
<tr>
<td>EU/1/12/756/002</td>
<td>28</td>
</tr>
<tr>
<td>EU/1/12/756/003</td>
<td>30</td>
</tr>
<tr>
<td>EU/1/12/756/004</td>
<td>50</td>
</tr>
<tr>
<td>EU/1/12/756/005</td>
<td>56</td>
</tr>
<tr>
<td>EU/1/12/756/006</td>
<td>84</td>
</tr>
<tr>
<td>EU/1/12/756/007</td>
<td>90</td>
</tr>
<tr>
<td>EU/1/12/756/008</td>
<td>98</td>
</tr>
<tr>
<td>EU/1/12/756/009</td>
<td>100</td>
</tr>
</tbody>
</table>

13. MANUFACTURER’S BATCH NUMBER

Lot

14. GENERAL CLASSIFICATION FOR SUPPLY

15. INSTRUCTIONS ON USE

16. INFORMATION IN BRAILLE

Glidipion 15 mg

17. UNIQUE IDENTIFIER – 2D BARCODE

2D barcode carrying the unique identifier included.

18. UNIQUE IDENTIFIER – HUMAN READABLE DATA

PC:
SN:
NN:
### PARTICULARS TO APPEAR ON THE OUTER PACKAGING

#### CARTON

1. **NAME OF THE MEDICINAL PRODUCT**

Glidipion 30 mg tablets

pioglitazone

2. **STATEMENT OF ACTIVE SUBSTANCE(S)**

Each tablet contains 30 mg pioglitazone (as hydrochloride).

3. **LIST OF EXCIPIENTS**

Contains lactose monohydrate. See leaflet for further information.

4. **PHARMACEUTICAL FORM AND CONTENTS**

<table>
<thead>
<tr>
<th>14 tablets</th>
<th>28 tablets</th>
<th>30 tablets</th>
<th>50 tablets</th>
<th>56 tablets</th>
<th>84 tablets</th>
<th>90 tablets</th>
<th>98 tablets</th>
<th>100 tablets</th>
</tr>
</thead>
</table>

5. **METHOD AND ROUTE(S) OF ADMINISTRATION**

Read the package leaflet before use.

Oral use.

6. **SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN**

Keep out of the sight and reach of children.

7. **OTHER SPECIAL WARNING(S), IF NECESSARY**

8. **EXPIRY DATE**

EXP

9. **SPECIAL STORAGE CONDITIONS**
10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE

11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER

Actavis Group PTC ehf.
220 Hafnarfjörður
Iceland

12. MARKETING AUTHORISATION NUMBER(S)

EU/1/12/756/010 [14 tablets]
EU/1/12/756/011 [28 tablets]
EU/1/12/756/012 [30 tablets]
EU/1/12/756/013 [50 tablets]
EU/1/12/756/014 [56 tablets]
EU/1/12/756/015 [84 tablets]
EU/1/12/756/016 [90 tablets]
EU/1/12/756/017 [98 tablets]
EU/1/12/756/018 [100 tablets]

13. MANUFACTURER’S BATCH NUMBER

Lot

14. GENERAL CLASSIFICATION FOR SUPPLY

15. INSTRUCTIONS ON USE

16. INFORMATION IN BRAILLE

Glidipion 30 mg

17. UNIQUE IDENTIFIER – 2D BARCODE

2D barcode carrying the unique identifier included.

18. UNIQUE IDENTIFIER – HUMAN READABLE DATA

PC:          
SN:          
NN:          

Medicinal Product no longer authorised
### PARTICULARS TO APPEAR ON THE OUTER PACKAGING CARTON

#### 1. NAME OF THE MEDICINAL PRODUCT

Glidipion 45 mg tablets
pioglitazone

#### 2. STATEMENT OF ACTIVE SUBSTANCE(S)

Each tablet contains 45 mg pioglitazone (as hydrochloride).

#### 3. LIST OF EXCIPIENTS

Contains lactose monohydrate. See leaflet for further information.

#### 4. PHARMACEUTICAL FORM AND CONTENTS

<table>
<thead>
<tr>
<th>Quantity</th>
<th>Number</th>
</tr>
</thead>
<tbody>
<tr>
<td>14 tablets</td>
<td></td>
</tr>
<tr>
<td>28 tablets</td>
<td></td>
</tr>
<tr>
<td>30 tablets</td>
<td></td>
</tr>
<tr>
<td>50 tablets</td>
<td></td>
</tr>
<tr>
<td>56 tablets</td>
<td></td>
</tr>
<tr>
<td>84 tablets</td>
<td></td>
</tr>
<tr>
<td>90 tablets</td>
<td></td>
</tr>
<tr>
<td>98 tablets</td>
<td></td>
</tr>
<tr>
<td>100 tablets</td>
<td></td>
</tr>
</tbody>
</table>

#### 5. METHOD AND ROUTE(S) OF ADMINISTRATION

Read the package leaflet before use.

Oral use.

#### 6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN

Keep out of the sight and reach of children.

#### 7. OTHER SPECIAL WARNING(S), IF NECESSARY

#### 8. EXPIRY DATE

EXP

#### 9. SPECIAL STORAGE CONDITIONS

Medicinal Product no longer authorised
10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE

11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER

Actavis Group PTC ehf.
220 Hafnarfjörður
Iceland

12. MARKETING AUTHORISATION NUMBER(S)

EU/1/12/756/019 [14 tablets]
EU/1/12/756/020 [28 tablets]
EU/1/12/756/021 [30 tablets]
EU/1/12/756/022 [50 tablets]
EU/1/12/756/023 [56 tablets]
EU/1/12/756/024 [84 tablets]
EU/1/12/756/025 [90 tablets]
EU/1/12/756/026 [98 tablets]
EU/1/12/756/027 [100 tablets]

13. MANUFACTURER’S BATCH NUMBER

Lot

14. GENERAL CLASSIFICATION FOR SUPPLY

15. INSTRUCTIONS ON USE

16. INFORMATION IN BRAILLE

Glidipion 45 mg

17. UNIQUE IDENTIFIER – 2D BARCODE

2D barcode carrying the unique identifier included.

18. UNIQUE IDENTIFIER – HUMAN READABLE DATA

PC:
SN:
NN:
### MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR STRIPS

**BLISTER**

1. **NAME OF THE MEDICINAL PRODUCT**

   Glidipion 15 mg tablets  
   pioglitazone

2. **NAME OF THE MARKETING AUTHORISATION HOLDER**

   Actavis Group PTC ehf. (logo)

3. **EXPIRY DATE**

   EXP

4. **BATCH NUMBER**

   Lot

5. **OTHER (FOR CALENDARISED PACKS SIZES OF 14, 28, 56, 84 AND 98 TABLETS ONLY)**

   Mon,  
   Tue,  
   Wed,  
   Thu,  
   Fri,  
   Sat,  
   Sun.
### MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR STRIPS

**BLISTER**

1. **NAME OF THE MEDICINAL PRODUCT**

   Glidipion 30 mg tablets
   pioglitazone

2. **NAME OF THE MARKETING AUTHORISATION HOLDER**

   Actavis Group PTC ehf. (logo)

3. **EXPIRY DATE**

   EXP

4. **BATCH NUMBER**

   Lot

5. **OTHER (FOR CALENDARISED PACKS SIZES OF 14, 28, 56, 84 AND 98 TABLETS ONLY)**

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Medicinal Product no longer authorised
<table>
<thead>
<tr>
<th>MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR STRIPS</th>
</tr>
</thead>
<tbody>
<tr>
<td>BLISTER</td>
</tr>
<tr>
<td>1. NAME OF THE MEDICINAL PRODUCT</td>
</tr>
<tr>
<td>Glidipion 45 mg tablets</td>
</tr>
<tr>
<td>pioglitazone</td>
</tr>
<tr>
<td>2. NAME OF THE MARKETING AUTHORISATION HOLDER</td>
</tr>
<tr>
<td>Actavis Group PTC ehf. (logo)</td>
</tr>
<tr>
<td>3. EXPIRY DATE</td>
</tr>
<tr>
<td>EXP</td>
</tr>
<tr>
<td>4. BATCH NUMBER</td>
</tr>
<tr>
<td>Lot</td>
</tr>
<tr>
<td>5. OTHER (FOR CALENDARISED PACKS SIZES OF 14, 28, 56, 84 AND 98 TABLETS ONLY)</td>
</tr>
<tr>
<td>Mon.</td>
</tr>
<tr>
<td>Tue.</td>
</tr>
<tr>
<td>Wed.</td>
</tr>
<tr>
<td>Thu.</td>
</tr>
<tr>
<td>Fri.</td>
</tr>
<tr>
<td>Sat.</td>
</tr>
<tr>
<td>Sun.</td>
</tr>
</tbody>
</table>

Medicinal Product no longer authorised
B. PACKAGE LEAFLET
Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.
- Keep this leaflet. You may need to read it again.
- If you have any further questions, ask your doctor or pharmacist.
- This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours.
- If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4.

What is this leaflet:
1. What Glidipion is and what it is used for
2. What you need to know before you take Glidipion
3. How to take Glidipion
4. Possible side effects
5. How to store Glidipion
6. Contents of the pack and other information

1. What Glidipion is and what it is used for

Glidipion contains pioglitazone. It is an anti-diabetic medicine used to treat type 2 (non-insulin dependent) diabetes mellitus, when metformin is not suitable or has failed to work adequately. This is the diabetes that usually develops in adulthood.

Glidipion helps control the level of sugar in your blood when you have type 2 diabetes by helping your body make better use of the insulin it produces. Your doctor will check whether Glidipion is working 3 to 6 months after you start taking it.

Glidipion may be used on its own in patients who are unable to take metformin, and where treatment with diet and exercise has failed to control blood sugar or may be added to other therapies (such as metformin, sulphonylurea or insulin) which have failed to provide sufficient control of blood sugar.

2. What you need to know before you take Glidipion

Do not take Glidipion
- if you are hypersensitive (allergic) to pioglitazone or any of the other ingredients of Glidipion (see section 6 for a list of ingredients).
- if you have heart failure or have had heart failure in the past.
- if you have liver disease.
- if you have had diabetic ketoacidosis (a complication of diabetes causing rapid weight loss, nausea or vomiting).
- if you have or have ever had bladder cancer.
- if you have blood in your urine that your doctor has not checked.
**Warnings and precautions**

Talk to your doctor before you start to take this medicine:

- if you retain water (fluid retention) or have heart failure problems and in particular if you are over 75 years old. If you take anti-inflammatory medicines which can also cause fluid retention and swelling, you must also tell your doctor.
- if you have a special type of diabetic eye disease called macular oedema (swelling of the back of the eye).
- if you have cysts on your ovaries (polycystic ovary syndrome). There may be an increased possibility of becoming pregnant because you may ovulate again when you take Glidipion. If this applies to you, use appropriate contraception to avoid the possibility of an unplanned pregnancy.
- if you have a problem with your liver or heart. Before you start taking Glidipion you will have a blood sample taken to check your liver function. This check may be repeated at intervals. Some patients with long-standing type 2 diabetes mellitus and heart disease or previous stroke who were treated with pioglitazone and insulin experienced the development of heart failure. Inform your doctor as soon as possible if you experience signs of heart failure such as unusual shortness of breath or rapid increase in weight or localised swelling (oedema).

If you take Glidipion with other medicines for diabetes, it is more likely that your blood sugar could fall below the normal level (hypoglycaemia).

You may also experience a reduction in blood count (anaemia).

**Broken bones**

A higher number of bone fractures was seen in patients, particularly women taking pioglitazone. Your doctor will take this into account when treating your diabetes.

**Children and adolescents**

Use in children under 18 years is not recommended.

**Other medicines and Glidipion**

Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.

You can usually continue to take other medicines whilst you are being treated with Glidipion. However, certain medicines are especially likely to affect the amount of sugar in your blood:

- gemfibrozil (used to lower cholesterol)
- rifampicin (used to treat tuberculosis and other infections)

Tell your doctor or pharmacist if you are taking any of these. Your blood sugar will be checked, and your dose of Glidipion may need to be changed.

**Glidipion with food and drink**

You may take your tablets with or without food. You should swallow the tablets with a glass of water.

**Pregnancy and breastfeeding**

If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking this medicine.

Your doctor will advise you to discontinue this medicine.

**Driving and using machines**

Pioglitazone will not affect your ability to drive or use machines but take care if you experience abnormal vision.

**Glidipion contains lactose monohydrate**

If you have been told by your doctor that you have intolerance to some sugars, contact your doctor before taking Glidipion.
3. **How to take Glidipion**

Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.

The usual starting dose is one tablet of 15 mg or 30 mg of pioglitazone to be taken once daily. Your doctor may increase the dose to a maximum of 45 mg once a day. Your doctor will tell you the dose to take.

If you have the impression that the effect of Glidipion is too weak, talk to your doctor.

Glidipion can be taken with or without food.

When Glidipion is taken in combination with other medicines used to treat diabetes (such as insulin, chlorpropamide, glibenclamide, gliclazide, tolbutamide) your doctor will tell you whether you need to take a smaller dose of your medicines.

Your doctor will ask you to have blood tests periodically during treatment with Glidipion. This is to check that your liver is working normally.

If you are following a diabetic diet, you should continue with this while you are taking Glidipion.

Your weight should be checked at regular intervals; if your weight increases, inform your doctor.

**If you take more Glidipion than you should**

If you accidentally take too many tablets, or if someone else or a child takes your medicine, talk to a doctor or pharmacist immediately. Your blood sugar could fall below the normal level and can be increased by taking sugar. It is recommended that you carry some sugar lumps, sweets, biscuits or sugary fruit juice.

**If you forget to take Glidipion**

Take Glidipion daily as prescribed. However if you miss a dose, just carry on with the next dose as normal. Do not take a double dose to make up for a forgotten tablet.

For the 14, 28, 56, 84 and 98 tablets pack sizes, you can check the day on which you last took a tablet of Glidipion by referring to the calendar printed on the blister.

**If you stop taking Glidipion**

Glidipion should be used every day to work properly. If you stop using Glidipion, your blood sugar may go up. Talk to your doctor before stopping this treatment.

If you have any further questions on the use of this medicine, ask your doctor or pharmacist.

4. **Possible side effects**

Like all medicines, this medicine can cause side effects, although not everybody gets them.

In particular, patients have experienced the following serious side effects:

Heart failure has been experienced commonly (up to 1 in 10 people) in patients taking pioglitazone in combination with insulin. Symptoms are unusual shortness of breath or rapid increase in weight or localised swelling (oedema). If you experience any of these, especially if you are over the age of 65, seek medical advice straight away.

Bladder cancer has been experienced uncommonly (up to 1 in 100 people) in patients taking pioglitazone. Signs and symptoms include blood in your urine, pain when urinating or a sudden need to urinate. If you experience any of these, talk to your doctor as soon as possible.
Localised swelling (oedema) has also been experienced very commonly in patients taking pioglitazone in combination with insulin. If you experience this side effect, talk to your doctor as soon as possible.

Broken bones have been reported commonly (up to 1 in 10 people) in female patients taking pioglitazone and have also been reported in male patients (frequency cannot be estimated from the available data) taking pioglitazone. If you experience this side effect, talk to your doctor as soon as possible.

Blurred vision due to swelling (or fluid) at the back of the eye (frequency not known) has also been reported in patients taking pioglitazone. If you experience this symptom for the first time, talk to your doctor as soon as possible. Also, if you already have blurred vision and the symptom gets worse, talk to your doctor as soon as possible.

Allergic reactions have been reported (frequency not known) in patients taking Glidipion. If you have a serious allergic reaction, including hives and swelling of the face, lips, tongue, or throat that may cause difficulty in breathing or swallowing stop taking this medicine and talk to your doctor as soon as possible.

The other side effects that have been experienced by some patients taking pioglitazone:

Common (may affect up to 1 in 10 people)
- respiratory infection
- abnormal vision
- weight gain
- numbness

Uncommon (may affect up to 1 in 100 people)
- inflammation of the sinuses (sinusitis)
- difficulty sleeping (insomnia)

Not known (frequency cannot be estimated from the available data)
- increase in liver enzymes
- allergic reactions

The other side effects that have been experienced by some patients when pioglitazone is taken with other antidiabetic medicines are:

Very common (may affect more than 1 in 10 people)
- decreased blood sugar (hypoglycaemia)

Common (may affect up to 1 in 10 people)
- headache
- dizziness
- joint pain
- impotence
- back pain
- shortness of breath
- small reduction in red blood cell count
- flatulence (wind)

Uncommon (may affect up to 1 in 100 people)
- sugar in urine, proteins in urine
- increase in enzymes
- spinning sensation (vertigo)
- sweating
- tiredness
- increased appetite

**Reporting of side effects**

If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects you can help provide more information on the safety of this medicine.

5. **How to store Glidipion**

Keep out of the sight and reach of children.

Do not use Glidipion after the expiry date which is stated on the carton and the blister pack after the word “EXP”. The expiry date refers to the last day of that month.

This medicine does not require any special storage precautions.

Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help to protect the environment.

6. **Contents of the pack and other information**

**What Glidipion contains**

- The active substance is pioglitazone.
  - Each tablet contains 15 mg, 30 mg or 45 mg of pioglitazone (as hydrochloride).
  - Each tablet contains 15 mg of pioglitazone (as hydrochloride).
  - Each tablet contains 30 mg of pioglitazone (as hydrochloride).
  - Each tablet contains 45 mg of pioglitazone (as hydrochloride).
- The other ingredients are lactose monohydrate, hydroxypropylcellulose, carmellose calcium and magnesium stearate.

**What Glidipion looks like and contents of the pack**

Glidipion 15 mg tablets are white, round, flat, bevelled, 5.5 mm in diameter and engraved with ‘TZ15’ on one side.

Glidipion 30 mg tablets are white, round, flat, bevelled, 7 mm in diameter and engraved with ‘TZ30’ on one side.

Glidipion 45 mg tablets are white, round, flat, bevelled, 8 mm in diameter and engraved with ‘TZ45’ on one side.

The tablets are supplied in aluminium blister packs of 14, 28, 30, 50, 56, 84, 90, 98 and 100 tablets.

The packs with 14, 28, 56, 84 and 98 tablets contain blisters with abbreviations for days of the week printed on the blister (Mon., Tue., Wed., Thu., Fri., Sat., Sun.).

Not all the pack sizes may be marketed.

**Marketing Authorisation Holder and Manufacturer**

*Marketing Authorisation Holder*
Actavis Group PTC ehf.
Reykjavíkurvegi 76-78
220 Hafnarfjörður
Iceland
Manufacturer
Actavis Ltd.
BLB 016 Bulebel Industrial Estate
Zejtun ZTN 3000
Malta

For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder:

Belgie/Belgique/Belgien
Actavis Group PTC ehf.
Island / Islande / Island

Belgium
Actavis Group PTC ehf.
Island / Islande / Island

България
Актавис ЕАД
Тел.: +359 2 489 95 85

Bulgaria
Актавис ЕАД
Тел.: +359 2 489 95 85

Česká republika
Teva Pharmaceuticals CR, s.r.o.
Tel: +420 251 007 111

Česka republika
Teva Pharmaceuticals CR, s.r.o.
Tel: +420 251 007 111

Danmark
Teva Denmark A/S
Tlf: +45 44 98 55 11

Danmark
Teva Denmark A/S
Tlf: +45 44 98 55 11

Deutschland
Actavis Group PTC ehf.
Island

Deutschland
Actavis Group PTC ehf.
Island

Eesti
UAB "Sicor Biotech" Eesti filiaal
Tel: +372 661 0801

Eesti
UAB "Sicor Biotech" Eesti filiaal
Tel: +372 661 0801

Ελλάδα
Specifar ABEE
Τηλ.: +30 210 5401500

Ελλάδα
Specifar ABEE
Τηλ.: +30 210 5401500

España
Actavis Group PTC ehf.
Islandia

España
Actavis Group PTC ehf.
Islandia

France
Actavis Group PTC ehf.
Islande

France
Actavis Group PTC ehf.
Islande

Hrvatska
Pliva Hrvatska d.o.o.
Tel: +385 1 37 20 000

Hrvatska
Pliva Hrvatska d.o.o.
Tel: +385 1 37 20 000

Ireland
Actavis Ireland Limited
Tel: +353 (0)21 4619040

Ireland
Actavis Ireland Limited
Tel: +353 (0)21 4619040

Lietuva
UAB "Sicor Biotech"
Tel: +370 5 266 0203

Lietuva
UAB "Sicor Biotech"
Tel: +370 5 266 0203

Luxembourg/Luxemburg
Actavis Group PTC ehf.
Islande / Island

Luxembourg/Luxemburg
Actavis Group PTC ehf.
Islande / Island

Magyarország
Teva Gyógyszergyár Zrt.
Tel.: +36 1 288 6400

Magyarország
Teva Gyógyszergyár Zrt.
Tel.: +36 1 288 6400

Malta
Actavis Ltd.
Tel: +3562 162633

Malta
Actavis Ltd.
Tel: +3562 162633

Nederland
Actavis Group PTC ehf.
Island

Nederland
Actavis Group PTC ehf.
Island

Norge
Teva Norway AS
Tlf: +47 66 77 55 90

Norge
Teva Norway AS
Tlf: +47 66 77 55 90

Österreich
ratiopharm Arzneimittel Vertriebs-GmbH
Tel: +43(0)1 97007 0

Österreich
ratiopharm Arzneimittel Vertriebs-GmbH
Tel: +43(0)1 97007 0

Polska
Actavis Export Int. Ltd., Malta.
Kontakt w Polsce:
Tel: (+48 22) 512 29 00

Polska
Actavis Export Int. Ltd., Malta.
Kontakt w Polsce:
Tel: (+48 22) 512 29 00

Portugal
Aurovitas, Unipessoal, Lda
Tel: +351 214 185 104

Portugal
Aurovitas, Unipessoal, Lda
Tel: +351 214 185 104

România
Teva Pharmaceuticals S.R.L
Tel: +4021 230 65 24

România
Teva Pharmaceuticals S.R.L
Tel: +4021 230 65 24

Slovenija
Pliva Ljubljana d.o.o.
Tel: +386 1 58 90 390

Slovenija
Pliva Ljubljana d.o.o.
Tel: +386 1 58 90 390
Ísland
Actavis Group PTC ehf.
Sími: +354 550 3300

Slovenská republika
TEVA Pharmaceuticals Slovakia s.r.o
Tel: +421 2 57 26 79 11

Italia
Aurobindo Pharma (Italia) s.r.l.
Tel: +39 0296392601

Suomi/Finland
ratiopharm Oy
Puh/Tel: +358 (0)20 180 5900

Κύπρος
Specifar ABEE
Τηλ: +30 210 5401500
Ελλάδα

Sverige
Teva Sweden AB
+46 42 12 11 00

Latvija
UAB "Sicor Biotech" filiāle Latvijā
Tel: +371 673 23 666

United Kingdom
Actavis UK Limited
Tel: +44 1271 385257

This leaflet was last revised in {MM/YYYY}.

Detailed information on this medicine is available on the European Medicines Agency web site: http://www.ema.europa.eu/.